Instil Bio, Inc..
TIL.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Instil Bio, Inc. is a biopharmaceutical company focused on developing adoptive cell therapies for the treatment of cancer. The company's lead product candidate is TIL (Tumor-Infiltrating Lymphocytes) therapies, which involve using a patient's own immune cells to target and destroy cancer cells. Inst...Show More
Better Health for All
-40
Instil Bio's core business is the development of cancer therapies, with its entire active pipeline focused on revolutionary health benefits, including TIL therapies for melanoma, HNSCC, and cervical cancer, and bispecific antibodies for NSCLC. Clinical trials for TIL therapies have shown objective response rates of 67% in advanced melanoma patients
1
and 41% in a meta-analysis of metastatic melanoma.
2
However, the company has discontinued several programs, including its lead tumor-infiltrating lymphocyte therapy in 2022,
3
the ITIL-306 program in 2024,
4
and AXN-2510 and AXN-27M in 2026,
5
without providing specific reasons, leading to analyst speculation about clinical data issues.
6
The company's R&D expenses were $5.4 million for Q1 2025, a decrease from $7.3 million in Q1 2024.
7
Instil Bio reduced its U.S. workforce by approximately 60% in Q1 2023
8
and planned a 61% reduction in its UK workforce in January 2024.
9
The company is subject to stringent and evolving data privacy and security regulations.
10
It has structured crisis response protocols but acknowledges potential disruptions from disease outbreaks.
11
Clinical trials are conducted under protocols, reviewed by independent IRBs, and follow GCP, but some studies include oversight by a data safety monitoring board, not all.
12
The company discusses patent term extensions and orphan drug exclusivity, which can impact market competition.
13
Fair Money & Economic Opportunity
0
Instil Bio, Inc. is a biopharmaceutical company focused on developing adoptive cell therapies for cancer. The ethical value 'Fair Money & Economic Opportunity' assesses activities related to lending, insuring, moving, or storing money for consumers. The provided articles describe Instil Bio's operations in research, development, clinical trials, and manufacturing of cell therapies, along with its financial performance (e.g., IPO, net losses, R&D expenses) and corporate governance. None of the articles explicitly state that Instil Bio offers or does not offer consumer financial products or services. Therefore, there is no specific, concrete data point in the evidence to score any of the KPIs under this value, as they all pertain to financial services. As per the rules, KPIs without explicit evidence must be omitted.
Fair Pay & Worker Respect
-20
Employee engagement is rated 2.2 out of 5 stars by employees.
1
The company experienced significant layoffs, including 15 employees in US manufacturing in February 2023 and 60% of staff in December 2022.
2
CEO total compensation was $5.32 million.
3
Employee-reported salaries include $109,982 per year for a Scientific Research & Development Scientist and $41.27 per hour for a Cell Culture Technician.
4
The average compensation and benefits rating from employees is 3.1 out of 5 stars.
5
Fair Trade & Ethical Sourcing
0
No specific data related to fair trade, ethical sourcing, or supplier diversity is present in the provided articles. The documents do not contain information on fair-trade certification, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend.
1
Honest & Fair Business
-40
The company has a 'Whistleblower Policy for Accounting and Auditing Matters' and provides a Compliance Hotline with toll-free numbers for the USA, Canada, and the UK.
1
A Compliance Officer is responsible for promptly investigating reported Code of Conduct violations, but there is no evidence of independent investigation processes.
2
The Board is structured with a majority of independent directors, and only independent directors serve on the Audit, Compensation, and Nominating and Corporate Governance Committees.
3
However, a specific percentage of conflict-free board members is not provided. The company has a separate 'Anti-Corruption Policy' and its Code of Business Conduct and Ethics, amended October 1, 2024, requires personnel to comply with applicable laws in all countries of operation, including those prohibiting bribery and corruption.
4
It also sets a gift and entertainment limit of $250 and prohibits cash gifts, and includes annual acknowledgment requirements for its policy.
5
Kind to Animals
0
No specific evidence regarding Instil Bio, Inc.'s (TIL.US) practices or policies related to animal welfare, animal testing, or animal-derived inputs was found in the provided articles. The articles discuss general industry trends, advocacy by PETA, and commitments by EFPIA members, but do not explicitly mention TIL.US or provide company-specific data for any of the KPIs.
No War, No Weapons
0
No relevant evidence was found in the provided article to assess TIL.US against the 'No War, No Weapons' ethical value.
1
The article explicitly states it contains no data relevant to TIL.US or this value.
2
Planet-Friendly Business
-50
The company has no SBTi commitment.
1
No other specific, quantitative data points related to planet-friendly business practices were found in the provided articles.
2
Respect for Cultures & Communities
0
No evidence available to assess Instil Bio, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
-50
Instil Bio's privacy policy, effective November 19, 2020, grants users rights to access, correct, delete, obtain machine-readable copies of their personal information, restrict processing, and object to legitimate interest processing.
1
However, the company does not currently respond to 'Do Not Track' signals.
2
The company states it takes steps to detect and remediate vulnerabilities, and its Audit Committee oversees information security risk management, including data privacy and cybersecurity.
3
It also mentions the use of automated tools to identify certain risks within the collaboration environment.
4
The company is subject to various U.S. and foreign data privacy and security laws, including HIPAA, HITECH, GDPR, and CCPA/CPRA, and uses personal information to comply with these regulations.
5
Potential fines for non-compliance include up to $7,500 per CCPA violation and up to £17.5 million or 4% of annual global revenue under UK GDPR.
6
Zero Waste & Sustainable Products
0
No specific, quantitative data points related to waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education were found in the provided articles. The articles discuss construction projects, clinical trial manufacturing issues, and a general ESG assessment score for 'Reduced Waste' (33.8).
1
But this score is not a direct, quantitative metric for any of the specific KPIs in the rubric.